Actinium Pharmaceuticals Inc (ATNM)
7.80
+0.10
(+1.30%)
USD |
NYAM |
May 01, 16:00
7.80
0.00 (0.00%)
After-Hours: 20:00
Actinium Pharmaceuticals Cash from Financing (TTM): 14.87M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 14.87M |
September 30, 2023 | 18.57M |
June 30, 2023 | 17.29M |
March 31, 2023 | 23.90M |
December 31, 2022 | 23.11M |
September 30, 2022 | 19.02M |
June 30, 2022 | 23.22M |
March 31, 2022 | 20.86M |
December 31, 2021 | 35.22M |
September 30, 2021 | 56.25M |
June 30, 2021 | 50.24M |
March 31, 2021 | 87.97M |
December 31, 2020 | 76.18M |
September 30, 2020 | 54.30M |
June 30, 2020 | 54.88M |
March 31, 2020 | 17.86M |
December 31, 2019 | 17.11M |
September 30, 2019 | 20.32M |
June 30, 2019 | 19.98M |
March 31, 2019 | 3.903M |
December 31, 2018 | 16.98M |
September 30, 2018 | 13.84M |
June 30, 2018 | 28.80M |
March 31, 2018 | 31.77M |
December 31, 2017 | 18.81M |
Date | Value |
---|---|
September 30, 2017 | 28.04M |
June 30, 2017 | 13.72M |
March 31, 2017 | 16.29M |
December 31, 2016 | 15.78M |
September 30, 2016 | 11.39M |
June 30, 2016 | 13.08M |
March 31, 2016 | 20.53M |
December 31, 2015 | 37.53M |
September 30, 2015 | 32.70M |
June 30, 2015 | 31.71M |
March 31, 2015 | 31.26M |
December 31, 2014 | 15.71M |
September 30, 2014 | 18.57M |
June 30, 2014 | 17.19M |
March 31, 2014 | 9.126M |
December 31, 2013 | 6.224M |
September 30, 2013 | 7.797M |
June 30, 2013 | 7.830M |
March 31, 2013 | 4.404M |
December 31, 2012 | 5.130M |
September 30, 2012 | 6.665M |
June 30, 2012 | 6.665M |
March 31, 2012 | 6.681M |
December 31, 2011 | 6.025M |
September 30, 2011 | 0.0251M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
14.87M
Minimum
Dec 2023
87.97M
Maximum
Mar 2021
34.27M
Average
23.11M
Median
Dec 2022
Cash from Financing (TTM) Benchmarks
Perspective Therapeutics Inc | 0.785M |
Eli Lilly and Co | 3.496B |
Cellectar Biosciences Inc | 22.94M |
Outlook Therapeutics Inc | 5.120M |
Bristol-Myers Squibb Co | 8.278B |